CD44 variant isoforms (e.g., CD44v6 and CD44v3) contribute to the pre-metastatic niche, tumor progression, and chemotherapy resistance through pathways involving Nanog, Oct-Sox2-Nanog, and other regulators; see Figure 4 [86,87]. The gene discussed is NANOG; the disease is neoplasm.